Hims & Hers Health (NYSE:HIMS) has taken investors on a wild ride in 2025. The stock surged nearly 200% earlier this year, reaching an ...

Hims & Hers Health stock corrected after earnings because of the outlook on its key GLP-1 medication. See why I rate HIMS a ...

The knockoff surge was led by Hims & Hers Health, the telehealth firm that began selling the drugs last spring.

Many treatments are available, and with the popularity of online and mail-order services in recent years, two leaders are BlueChew and Hims. Both companies offer different ED treatments and a ...

Telehealth personalized care company Hims & Hers shuttered a central part of its dermatology offering, skincare brand Apostrophe, to "simplify" its dermatology offerings and operations ...

We are tool-using creatures with a long history of offloading mental labor. Cave paintings, for example, allowed our prehistoric relatives to share and preserve stories that would otherwise be ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

(CNN) — Scientists say they have the first recorded video evidence of narwhals using tusks not only to strike and manipulate fish during feeding but also engage in what appears to be playful ...

A view of the Hims smartphone app. Photo: Getty Images Hims & Hers Health will shut down Apostrophe, its personalized acne treatments dermatology business, the company said on Friday. Apostrophe ...

Hims & Hers is shutting down the dermatology business it acquired in 2021, BI has learned. It said it's closing the skincare site Apostrophe to centralize its teledermatology offerings. Hims ...

HIMS Stock's Valuation Looks Reasonable As stated above, HIMS stock's valuation looks reasonable now. Let's use a reverse DCF, as I did in my HIMS article from November, to figure out how much ...